BrightGene Bio-Medical Technology Co

BrightGene Bio-Medical Technology Co Stock-Based Compensation

The Stock-Based Compensation (SBC) of BrightGene Bio-Medical Technology Co (688166.SS) as of Nov 22, 2026 is 6.27 M CNY.

Stock-Based Compensation

6.27 MCNY

Last updated:

Stock-Based Compensation (SBC) of BrightGene Bio-Medical Technology Co is 2025 6.27 M CNY. Stock-Based Compensation (SBC) of BrightGene Bio-Medical Technology Co was 2024 0.00 CNY. It decreases by % higher compared to the previous year.

The BrightGene Bio-Medical Technology Co Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2024
0.00 CNY
Jan 1, 2025
6.27 M CNY
The BrightGene Bio-Medical Technology Co Stock-Based Compensation history
YEARStock-Based CompensationYoY
6.27 MCNY—
0.00CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BrightGene Bio-Medical Technology Co Stock analysis

What does BrightGene Bio-Medical Technology Co do? BrightGene Bio-Medical Technology Co., Ltd. generates revenue by researching, developing, and manufacturing biopharmaceuticals, medicines, and special generic active pharmaceutical ingredients and finished dosage forms. The company's product portfolio centers on antifungal, antiviral, and immunosuppressive APIs, alongside other APIs and preparations. Its generic drug offerings specifically include entecavir, caspofungin, micafungin, posaconazole, everolimus, and fondaparinux sodium. The firm sells these products to customers in both domestic and overseas markets. By leveraging its capabilities in producing essential active pharmaceutical ingredients and finished dosage forms, the company serves the broader pharmaceutical sector through its established manufacturing and research operations. BrightGene Bio-Medical Technology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BrightGene Bio-Medical Technology Co stock

Stock-Based Compensation (SBC) of BrightGene Bio-Medical Technology Co is 6.27 M CNY in 2025.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) BrightGene Bio-Medical Technology Co since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s BrightGene Bio-Medical Technology Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — BrightGene Bio-Medical Technology Co

All Key Metrics — BrightGene Bio-Medical Technology Co